Recurrent Glioblastoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The top 7 (US, EU4, UK, and Japan) recurrent glioblastoma markets are expected to exhibit a CAGR of 6.06% during 2025-2035.

The recurrent glioblastoma market has been comprehensively analyzed in IMARC's new report titled "Recurrent Glioblastoma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Recurrent glioblastoma refers to the return or progression of glioblastoma multiforme (GBM), which is the most aggressive and common form of malignant brain tumor. It is classified as a grade IV astrocytoma and typically exhibits rapid growth and invasive behavior within the brain. The disease can occur at the original site of the tumor or in nearby areas of the brain. It can also manifest as multiple lesions in different regions of the central nervous system. The common symptoms of the ailment include persistent or worsening headaches, convulsions, loss of consciousness, abnormal sensations and movements, cognitive decline, memory problems, difficulty concentrating, changes in personality, numbness, blurred vision, hearing loss, generalized weakness, etc. The diagnosis of recurrent glioblastoma involves a combination of imaging studies, clinical evaluation, and various additional procedures. The healthcare provider will initially perform a physical examination to assess the neurological function and overall health of the patient. Several diagnostic techniques, such as magnetic resonance imaging and positron emission tomography scans, are also utilized to determine the extent and location of the disease.

The increasing incidence of incomplete surgical resection, causing the small cancerous cells to regrow and multiply, is primarily driving the recurrent glioblastoma market. In addition to this, the rising prevalence of genetic mutations and alterations that lead to treatment resistance as well as contribute to the aggressive nature of tumors is also creating a positive outlook for the market. Moreover, the widespread adoption of molecularly targeted drugs, like bevacizumab, since they block specific signaling pathways involved in the proliferation of unhealthy tissues and the formation of new blood vessels, is further bolstering the market growth. Apart from this, the escalating application of tumor treating field therapy, which uses a device to emit alternating electric fields to disrupt cell division and limit disease progression, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy for the treatment of the ailment, owing to its several associated benefits, such as enhanced sensitivity to regimens, increased tumor suppression, and long-term therapeutic effects, is expected to drive the recurrent glioblastoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the recurrent glioblastoma market in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for recurrent glioblastoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the recurrent glioblastoma market in any manner.

Recent Developments:

• In March 2025, Vaximm AG announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination with avelumab (PD-L1 inhibitor) in patients with recurrent glioblastoma.
• In October 2024, Biodexa Pharmaceuticals announced an update in respect of its open-label Phase 1 study of MTX110 in recurrent glioblastoma.
• In June 2024, MediciNova, Inc. presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in glioblastoma. The clinical study included 62 patients, 36 with newly diagnosed glioblastoma and 26 with recurrent glioblastoma.

Drugs:

GLIADEL Wafer (polifeprosan 20 with carmustine implant) is recommended for patients with recurrent glioblastoma multiforme as a treatment option alongside surgery. GLIADEL Wafers contain 7.7 mg of carmustine, for a total dose of 61.6 mg when 8 wafers are implanted. Carmustine induces DNA crosslinking, disrupting tumor cell replication. By delivering high local concentrations while bypassing the blood–brain barrier, it targets residual malignant cells with minimal systemic exposure.

ACT 001 is a novel compound with potential in treating recurrent glioblastoma. It works by inhibiting the PD-L1 protein, which is often overexpressed in recurrent glioblastoma tumors, and also by directly targeting the STAT3 transcription factor, inhibiting its phosphorylation. This dual mechanism helps to release immune suppression mediated by the PD-1/PD-L1 checkpoint, potentially enhancing the body's anti-tumor immune response.

TTAC-0001, a fully human anti-VEGFR-2 (vascular endothelial growth factor receptor 2) monoclonal antibody developed by PharmAbcine, works by targeting and inhibiting VEGFR-2 in recurrent glioblastoma. This mechanism is crucial for combating angiogenesis, the process by which tumors develop new blood vessels to fuel their growth. By blocking VEGFR-2, TTAC-0001 prevents VEGF (vascular endothelial growth factor) from binding and activating the receptor, thus inhibiting downstream signaling pathways that promote angiogenesis. This ultimately restricts the blood supply to the tumor, hindering its growth and potentially improving treatment outcomes.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the recurrent glioblastoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the recurrent glioblastoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current recurrent glioblastoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the recurrent glioblastoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the recurrent glioblastoma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the recurrent glioblastoma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of recurrent glioblastoma across the seven major markets?
• What is the number of incident cases (2019-2035) of recurrent glioblastoma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of recurrent glioblastoma by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with recurrent glioblastoma across the seven major markets?
• What is the size of the recurrent glioblastoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend recurrent glioblastoma of?
• What will be the growth rate of patients across the seven major markets?

Recurrent Glioblastoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for recurrent glioblastoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the recurrent glioblastoma market?
• What are the key regulatory events related to the recurrent glioblastoma market?
• What is the structure of clinical trial landscape by status related to the recurrent glioblastoma market?
• What is the structure of clinical trial landscape by phase related to the recurrent glioblastoma market?
• What is the structure of clinical trial landscape by route of administration related to the recurrent glioblastoma market?